The venture capital company Invivo Partners, a member of CATALONIA.HEALTH, announced the closing of a €20 million Series A financing round for the biotechnology company Neumirna Therapeutics. The financing round was co-led by Angelini Ventures, with participation from existing investor Innovestor and several business angels.
After the investment in Neumirna Therapeutics, Luis Pareras, Managing Partner at Invivo Partners, and Thomas Thestrup, Senior Principal at Angelini Ventures, will join the Board of Directors of Neumirna, with Luis Pareras being appointed as a Chairman of the Board.
The funds raised in this financial round will enable Neumirna to advance its lead program (NMT-001) for the treatment of drug-resistant epilepsy. Additionally, the financing will support the expansion of Neumirna’s proprietary platform for the design of oligonucleotides targeting specific microRNAs in other neurological conditions, such as Parkinson’s Disease.
Moreover, Luis Pareras said, “Investing in Neumirna represents a unique opportunity to support a pioneering company in leveraging RNA technology to treat neurological diseases. As a neurosurgeon, I am deeply impressed by the innovative approach and the results of NMT-001. This is the first time I’ve seen an approach targeting the root cause of the disease rather than managing the seizures. Neumirna’s approach has the potential to change how we treat drug-resistant epilepsy, offering a transformative solution for patients with this devastating condition.”
Related news:
Comments